HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Antitumor effect after radiofrequency ablation of murine hepatoma is augmented by an active variant of CC Chemokine ligand 3/macrophage inflammatory protein-1alpha.

Abstract
Several chemokines are used for immunotherapy against cancers because they can attract immune cells such as dendritic and cytotoxic T cells to augment immune responses. Radiofrequency ablation (RFA) is used to locally eliminate cancers such as hepatocellular carcinoma (HCC), renal cell carcinoma, and lung cancer. Because HCC often recurs even after an eradicative treatment with RFA, additional immunotherapy is necessary. We treated tumor-bearing mice by administering ECI301, an active variant of CC chemokine ligand 3, after RFA. Mice were injected s.c. with BNL 1ME A.7R.1, a murine hepatoma cell line, in the bilateral flank. After the tumor became palpable, RFA was done on the tumor of one flank with or without ECI301. RFA alone eliminated the treated ipsilateral tumors and retarded the growth of contralateral non-RFA-treated tumors accompanied by massive T-cell infiltration. Injection of ECI301 augmented RFA-induced antitumor effect against non-RFA-treated tumors when administered to wild-type or CCR5-deficient but not CCR1-deficient mice. ECI301 also increased CCR1-expressing CD11c(+) cells in peripheral blood and RFA-treated tumors after RFA. Deficiency of CCR1 impairs accumulation of CD11c(+), CD4(+), and CD8(+) cells in RFA-treated tumors. Furthermore, in IFN-gamma-enzyme-linked immunospot assay, ECI301 augmented tumor-specific responses after RFA whereas deficiency of CCR1 abolished this augmentation. Thus, we proved that ECI301 further augments RFA-induced antitumor immune responses in a CCR1-dependent manner.
AuthorsNoriho Iida, Yasunari Nakamoto, Tomohisa Baba, Hidetoshi Nakagawa, Eishiro Mizukoshi, Makoto Naito, Naofumi Mukaida, Shuichi Kaneko
JournalCancer research (Cancer Res) Vol. 70 Issue 16 Pg. 6556-65 (Aug 15 2010) ISSN: 1538-7445 [Electronic] United States
PMID20663902 (Publication Type: Journal Article)
Copyright(c)2010 AACR.
Chemical References
  • Ccr1 protein, mouse
  • Chemokine CCL3
  • Receptors, CCR1
Topics
  • Animals
  • Catheter Ablation
  • Cell Line, Tumor
  • Chemokine CCL3 (biosynthesis, immunology, pharmacology)
  • Female
  • Liver Neoplasms, Experimental (drug therapy, surgery, therapy)
  • Lymphocytes, Tumor-Infiltrating (immunology)
  • Mice
  • Mice, Inbred BALB C
  • Mice, Nude
  • Receptors, CCR1 (biosynthesis, deficiency, immunology)
  • T-Lymphocytes (immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: